Intraoperative Radiation Therapy for Resectable Pancreatic Cancer

Status Active, not recruiting

Clinical Trial Summary

This phase II study is designed to investigate the efficacy of intraoperative radiotherapy after neoadjuvant chemotherapy in patients with resectable pancreatic cancer. The purpose of the study is to show the local recurrence rate after neoadjuvant chemotherapy and IORT is superior to that of surgical resection alone from the historical control. A total of 80 patients will be enrolled, and these patients will receive IORT of 10 Gy at 5 millimeter depth of the tumor bed, following neoadjuvant chemotherapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05181488
Study type	Interventional
Source	Gangnam Severance Hospital
Contact
Status	Active, not recruiting
Phase	N/A
Start date	April 2, 2020
Completion date	April 1, 2026

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05209074` - Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma	Phase 1
Not yet recruiting	`NCT05529940` - NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)	Phase 3
Terminated	`NCT02345460` - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study	Phase 2
Recruiting	`NCT02243007` - Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer	Phase 2
Recruiting	`NCT05679050` - Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer	Phase 2
Withdrawn	`NCT01694589` - A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer	Phase 0
Active, not recruiting	`NCT03138720` - Pre-operative Treatment for Patients With Untreated Pancreatic Cancer	Phase 2
Completed	`NCT01298011` - Study of Gemcitabine and Abraxane to Treat Potentially Operable Pancreatic Cancer	Phase 2
Completed	`NCT06363084` - A Retrospective Study for Nimotuzumab Plus Postoperative Adjuvant Chemotherapy for Resectable Pancreatic Cancer
Recruiting	`NCT04810910` - Personalized Neoantigen Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy	Phase 1
Completed	`NCT01992705` - Borderline Pancreas Study: FOLFIRINOX +SBRT	Early Phase 1
Completed	`NCT02047513` - Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer	Phase 2
Completed	`NCT02115022` - EUS vs. MDCT in Pancreatic Malignancy
Recruiting	`NCT03492671` - Testing the Combination of Two Approved Chemotherapy Drugs and Radiation Prior to Surgery in Localized Pancreatic Cancer	Phase 2
Terminated	`NCT05546411` - A Trial of NIS793 With FOLFIRINOX in Pancreatic Cancer	Phase 2
Not yet recruiting	`NCT06172036` - Irinotecan Liposome for Resectable Pancreatic Cancer With or Without Addebelizumab	Phase 2
Recruiting	`NCT05788744` - Implementing ctDNA and Circular DNA in Patients With Localized Pancreatic Cancer	N/A
Recruiting	`NCT04737551` - Adjuvant Chemoradiation Following Radical Resection of Pancreatic Ductal Adenocarcinoma, a Prospective Cohort Study
Recruiting	`NCT03822936` - Carbon Ions Radiation Therapy for Resectable or Borderline Resectable Pancreas Adenocarcinoma	Phase 2
Completed	`NCT03435536` - Surgery Impact on Circulating Tumor DNA in Pancreatic Cancer	N/A